ArticleBJU international2026
Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The cost-effectiveness of intraoperative margin assessment strategies during radical prostatectomy.BJU international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the impact of the presence, extent and location of positive surgical margins (PSMs) on the risk of biochemical recurrence (BCR) and metastases in a nationwide cohort of patients who underwent radical prostatectomy (RP) and had 5 years of follow-up.
methodsAll patients diagnosed with prostate cancer in the Netherlands between October 2015 and April 2016 who underwent RP were included in a prospective cohort. Data on these patients from the Netherlands Cancer Registry and the PALGA pathology registry were analysed. BCR was defined as a prostate-specific antigen (PSA) level ≥0.1 ng/mL >28 days after RP. Exclusion criteria were (neo)adjuvant treatment, pN1 disease, and salvage therapy initiated at PSA <0.1 μg/L. Multivariable Cox regression analyses were performed to evaluate the impact of PSM presence, extent and location on the risk of BCR and metastases.
resultsOf 998 patients, 311 (31%) had PSMs (median length 5.0 mm). Over 5 years of follow-up, 36% of patients experienced BCR and 11% developed metastases. PSMs ≥3 mm were associated with a significantly increased risk of BCR (hazard ratio [HR] 2.04, 95% confidence interval [CI] 1.58-2.64; P < 0.001) and metastases (HR 2.12, 95% CI 1.21-3.74; P = 0.009) compared to negative surgical margins. By contrast, PSMs <3 mm and PSM location did not significantly increase the risk of BCR or metastases.
conclusionOur study showed that PSMs ≥3 mm appear to be independently associated with an increased risk of BCR and metastases after RP. Therefore, avoiding or limiting the extent of PSMs during RP remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.